Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
mt-pharma.co.jp

See what CB Insights has to offer

Portfolio Exits

1

Partners & Customers

10

About Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma (TYO: 4508) is a research-driven pharmaceutical company based in Japan, specializing in research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease.

Mitsubishi Tanabe Pharma Headquarter Location

3-2-10, Dosho-machi Chuo-ku

Osaka, 541-8505,

Japan

+81-6-6205-5085

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mitsubishi Tanabe Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Mitsubishi Tanabe Pharma in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Latest Mitsubishi Tanabe Pharma News

FDA nod for oral formulation of amyotrophic lateral sclerosis drug Radicava

May 13, 2022

The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Developed by Japanese drugmaker Mitsubishi Tanabe Pharma, a part of Mitsubishi Chemical (TYO: 4188), Radicava ORS is an orally administered version of Radicava, which was originally  approved in 2017  as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou Gehrig’s… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Mitsubishi Tanabe Pharma Portfolio Exits

1 Portfolio Exit

Mitsubishi Tanabe Pharma has 1 portfolio exit. Their latest portfolio exit was Green Cross Pharmaceutical on .

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

Divestiture

1

Date

Exit

Divestiture

Companies

Valuation

Acquirer

Sources

1

Mitsubishi Tanabe Pharma Acquisitions

2 Acquisitions

Mitsubishi Tanabe Pharma acquired 2 companies. Their latest acquisition was NeuroDerm on October 18, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/18/2017

Other

$99M

$20.5M

Acq - P2P

11

9/18/2013

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

10/18/2017

9/18/2013

Investment Stage

Other

Other Venture Capital

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$20.5M

$99M

Note

Acq - P2P

Subscribe to see more

Sources

11

10

Mitsubishi Tanabe Pharma Partners & Customers

10 Partners and customers

Mitsubishi Tanabe Pharma has 10 strategic partners and customers. Mitsubishi Tanabe Pharma recently partnered with HitGen on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/25/2022

Partner

China

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest .

3

10/25/2021

Licensor

United States

08:07 ET New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patie...

In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. .

1

11/5/2020

Licensor

United States

Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scienti...

In Japan , Indonesia , and Taiwan , Janssen licenses distribution rights to REMICADE to Mitsubishi Tanabe Pharma Corporation .

1

8/18/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

4/8/2020

Licensor

China

Subscribe to see more

Subscribe to see more

10

Date

2/25/2022

10/25/2021

11/5/2020

8/18/2020

4/8/2020

Type

Partner

Licensor

Licensor

Partner

Licensor

Business Partner

Country

China

United States

United States

United States

China

News Snippet

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest .

08:07 ET New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patie...

In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. .

Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scienti...

In Japan , Indonesia , and Taiwan , Janssen licenses distribution rights to REMICADE to Mitsubishi Tanabe Pharma Corporation .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Mitsubishi Tanabe Pharma Team

2 Team Members

Mitsubishi Tanabe Pharma has 2 team members, including current President, Michihiro Tsuchiya.

Name

Work History

Title

Status

Michihiro Tsuchiya

President

Current

Natsuki Hayama

President

Former

Name

Michihiro Tsuchiya

Natsuki Hayama

Work History

Title

President

President

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.